- Expects Total Revenue Between $28.0 and $30.0 Million; Grows 146-163% Year-over-Year - - Expects Net Income Between $0.0 and $1.0 Million - - Expects Adjusted EBITDA Between $15.0 and $17.0 Million; Grows 64-86% Year-over-Year - - Schedules Second Quarter 2024 Earnings Release and Conference Call for Monday, August 12, 2024 - ORLANDO, Fla., July 18, 2024 (GLOBE NEWSWIRE) -- Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a pioneering alternative asset manager specializing in longevity and act ...

文章核心观点 - 阿巴克斯生命公司(Abacus)宣布以约2亿美元收购卡莱尔管理公司(Carlisle Management Company),这将为Abacus增加约20亿美元的资产管理规模 [1][2] - 此次收购有助于Abacus进一步拓展其作为全球替代资产管理公司和资产来源公司的地位 [2][3] - 收购后,Carlisle的专业团队和丰富经验将为Abacus的客户带来更多潜在机会和协同效应 [4][5] - 此次交易标志着Abacus ABL财富部门的重要时刻,将进一步巩固其在人寿结算市场的地位,为更广泛的投资者提供优质解决方案 [6] 交易细节 - 交易对价包括7350万美元的Abacus债券和930万股Abacus普通股,交易需要监管部门批准 [7] - 交易顾问方面,Abacus由Dynasty Investment Bank担任独家财务顾问,White & Case LLP和Elvinger S.à r.l. PLLC担任法律顾问;Carlisle由Manorhaven Capital, LLC担任独家财务顾问,ArentFox Schiff LLP、TS&P和Arendt & Medernach SA担任法律顾问 [8] 公司简介 Carlisle Management Company - 2008年成立,是一家领先的、高度多元化的全球投资管理公司 [9] - 拥有60多年的替代资产投资经验,在卢森堡受监管,由知名审计公司监督 [9] Abacus Life - 自2004年以来一直从事人寿保单收购和管理业务,已累计购买超过50亿美元的保单 [10] - 公司建立了制度化的原始和投资组合管理流程,拥有100多人的团队,与78家机构合作伙伴和3万家理财顾问建立了长期关系 [11] - 公司遵守HIPAA和隐私法,获得BBB A+认证 [11]

文章核心观点 - 公司Abacus Life, Inc.完成了一次规模为9200万美元的首次公开募股 [1] - 公司将使用募集资金用于运营、购买人寿保单、支持整体业务战略、营运资金和偿还债务等 [2] - 本次发行由多家投资银行担任联席主承销商 [3] 公司概况 - Abacus是一家专注于寿命长期和精算技术的领先垂直整合替代资产管理公司和做市商 [6] - 公司自2004年以来一直从消费者那里购买人寿保单并对其进行主动管理 [6] - 公司已累计购买了价值超过50亿美元的人寿保单,帮助数千名客户最大化人寿保险的价值 [6] - Abacus是唯一一家在纳斯达克交易所上市的人寿结算公司,股票代码为ABL [6] 风险因素 - 公司面临人寿结算行业需求增长不及预期的风险 [7] - 公司可能无法有效管理增长,保留和吸引新客户 [7] - 公司收入集中于少数客户,其中部分为关联方,存在一定风险 [7] - 人寿结算行业的负面趋势可能影响结算价值,如保费上升、被保人寿命延长、预期寿命报告假设错误等 [8] - 保险公司可能对某些人寿结算的合法性提出法律挑战 [8] - 公司知识产权和商业秘密可能遭到侵犯 [8] - 公司高度依赖于高管和关键员工 [8] - 行业监管环境的变化可能对公司产生不利影响 [8]

ORLANDO, Fla., June 24, 2024 (GLOBE NEWSWIRE) -- Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a pioneering alternative asset manager specializing in longevity and actuarial technology, today announced the closing of its oversubscribed underwritten public offering of 11,500,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,500,000 shares of common stock, at the public offering price of $8.00 per share. The gross proc ...

文章核心观点 - 公司Abacus Life(股票代码:ABL)正在进行公开发行,发行1000万股普通股,每股价格8美元[1][2][3] - 公司计划使用募集资金购买人寿保单、支持整体业务战略、用于营运资金和一般公司用途,也可能用于偿还债务[4] - 公开发行将增加总股本,稀释现有股东权益,可能是导致股价下跌的原因之一[5] - 发行价8美元较公司之前收盘价9.76美元有较大折扣,也可能拖累股价下跌[6] 公司信息 - Abacus Life是一家替代资产管理和做市商公司[1] - 本次公开发行由Piper Sandler & Co.、TD Securities (USA) LLC、B. Riley Securities和KKR Capital Markets LLC担任联席簿记管理人[2] 行业信息 - 无相关内容

Loading...Loading...U.S. stock futures were slightly lower this morning, with the Dow futures falling around 0.1% on Friday.Shares of Smith & Wesson Brands, Inc. SWBI fell sharply in today's pre-market trading after the company reported its fourth-quarter financial results.Smith & Wesson reported quarterly earnings of 45 cents per share, which beat the analyst consensus estimate of 34 cents. Quarterly sales came in at $159.1 million, which beat the analyst consensus estimate of $156.796 million, according t ...

文章核心观点 - 公司Abacus Life, Inc.("Abacus")完成了一次10,000,000股的公开发行,发行价格为每股8美元,预计募集资金总额约为8,000万美元[1] - 公司将使用募集资金用于公司运营,包括购买人寿保单、支持整体业务战略、营运资金和偿还/再融资债务[2] - 本次公开发行由Piper Sandler & Co.、TD Securities (USA) LLC、B. Riley Securities和KKR Capital Markets LLC担任联席主承销商[3] 公司概况 - Abacus是一家领先的垂直整合式另类资产管理公司和做市商,专注于寿命长期和精算技术[6] - 公司自2004年以来一直从消费者那里购买人寿保单,并对这些保单进行主动管理(通过交易、持有和/或服务)[6] - 公司已累计购买价值超过50亿美元的人寿保单,帮助数千名客户最大化人寿保险的价值[6] - Abacus是唯一一家在纳斯达克交易所上市的人寿结算公司,股票代码为ABL[6] 发展战略 - 公司正在通过三个突破性的新渠道"ABL Tech"、"ABL Wealth"和"ABL Longevity Funds"来民主化人寿保险行业[6] 风险因素 - 公司收入集中在少数客户(包括关联方)身上的风险[8(iv)] - 人寿结算行业出现负面趋势(如保费上升、被保人寿命延长、预期寿命报告方法和假设出错)可能影响人寿结算价值的风险[8(vi)] - 保险公司对某些人寿结算的合法性提出法律挑战的风险[8(vii)] - 公司知识产权(包括商标和商业秘密)被侵犯的风险[8(viii)] - 公司依赖高级管理人员和其他关键员工的风险[8(ix)] - 行业监管环境变化的风险[8(x)]

ORLANDO, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a pioneering alternative asset manager specializing in longevity and actuarial technology, today announced the pricing of its oversubscribed underwritten public offering of 10,000,000 shares of its common stock at a price to the public of $8.00 per share. In connection with the offering, the Company also granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of com ...

ORLANDO, Fla., June 13, 2024 (GLOBE NEWSWIRE) -- Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a pioneering alternative asset manager specializing in longevity and actuarial technology, today announced that it has commenced an underwritten public offering of 10,000,000 shares of its common stock. In connection with the offering, Abacus intends to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock at the public offering price. All of the sha ...

ORLANDO, Fla., June 13, 2024 (GLOBE NEWSWIRE) -- Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a pioneering alternative asset manager specializing in longevity and actuarial technology, today announced that it has commenced an underwritten public offering of 10,000,000 shares of its common stock. In connection with the offering, Abacus intends to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock at the public offering price. All of the sha ...